S1 Checklist: STROBE checklist. (Strobe checklist.docx)

STROBE Statement—Checklist of items that should be included in reports of ***cohort studies***

	Item No	Recommendation	Subsection	Page No.
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	Title page	1
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	Abstract, Core tip	3-4
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Introduction	6-7
Objectives	3	State specific objectives, including any prespecified hypotheses	Introduction	6-7
Methods				
Study design	4	Present key elements of study design early in the paper	Study collective	8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection		8-9
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Study collective, US Examination and EMUC-US	8-9
		(*b*) For matched studies, give matching criteria and number of exposed and unexposed	N/A	N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Study collective, US Examination and EMUC-US	8-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Study collective, US Examination and EMUC-US	8-9
Bias	9	Describe any efforts to address potential sources of bias	Statistical analysis	9
Study size	10	Explain how the study size was arrived at	Study collective	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Parameter, US examinations and EMUC-US	8-9
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	Statistical analysis	9
		(*b*) Describe any methods used to examine subgroups and interactions	Statistical analysis	9
		(*c*) Explain how missing data were addressed	Parameter	9
		(*d*) If applicable, explain how loss to follow-up was addressed	Parameter	9
		(*e*) Describe any sensitivity analyses	N/A	N/A

Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Patient collective, Lesion size, Localisation and distribution of EMUC-US, Change in EMUC-US pattern	10
		(b) Give reasons for non-participation at each stage	N/A	N/A
		(c) Consider use of a flow diagram	Figure 1	22
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Patient collective, Table 1	10
		(b) Indicate number of participants with missing data for each variable of interest	Parameter	10
		(c) Summarise follow-up time (eg, average and total amount)	Parameter	10
Outcome data	15*	Report numbers of outcome events or summary measures over time	Results	10-11
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Results	10-11
		(*b*) Report category boundaries when continuous variables were categorized	Results	10-11
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A	N/A
Discussion				
Key results	18	Summarise key results with reference to study objectives	Discussion	12-13
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Limits of the study	13
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence		12-13
Generalisability	21	Discuss the generalisability (external validity) of the study results		12-13
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based		1

*Give information separately for exposed and unexposed groups.
N/A not applicable